Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rang in aandelen #26672
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Aandeelprijs
$5.54
Laatst gesynchroniseerd: 2024-09-18
Marktkapitalisatie
$38.76M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Alimera Sciences, Inc. (ALIM)

Categorie

Winst voor Alimera Sciences, Inc. (ALIM)
Winst in Jun 2024 TTM: $-14.71M
Volgens de meest recente financiële verslagen van Alimera Sciences, Inc. bedraagt de huidige winst van het bedrijf $-14.71M. In 2022 behaalde het bedrijf een winst van $-18.08M, een daling ten opzichte van de winst van 2021, die $-3.93M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Alimera Sciences, Inc. van 2006 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-14.71M -26.61%
2023 $-20.05M 10.89%
2022 $-18.08M 359.56%
2021 $-3.93M -27.24%
2020 $-5.41M -47.13%
2019 $-10.23M -37.17%
2018 $-16.28M -25.47%
2017 $-21.84M -33.83%
2016 $-33.00M 8.15%
2015 $-30.52M -14.61%
2014 $-35.74M -22.70%
2013 $-46.23M 134.12%
2012 $-19.75M -12.30%
2011 $-22.52M 32.74%
2010 $-16.96M -59.95%
2009 $-42.36M -30.03%
2008 $-60.54M 383.70%
2007 $-12.52M 20.64%
2006 $-10.37M 0.00%
Winst van vergelijkbare bedrijven of concurrenten